No way the US market is lost - IMO. -----------------------------------------
What is the main reason 'in the first place' - that Brands have a protection period ? Its because 'The Brand had the to pay for the research leading up to FDA approval (like for Vascepa also the big R-I trial) - right.
In principle Amarin today - has no more expenses pr. produced bottle than generics (or they could move production to India - to level the costs compared to generics). ------------------------------------------
And then we are back to the AG debate. Even Du dicaster Amarin still hold the Brand name VASCEPA - so let say they vent into the market saying to everyone involved - we will match any generic price - with our AG Brand Vascepa.
You would expect AG part of total prescriptions to rise fast - wouldn't you ?
And lets imagine that Amarin AG Vascepa - aggressively regaining big parts of the US market this way - what is to stop them using a few dollars on some Marketing' - telling everyone that Original Brand Vascepa - is now on the market at generic prices ?
In theory you should be able to make prescriptions rise fast this way - pushing generics out' at the same time !
Market Data 
Markets 
AI
